Sign In
Buy SRPT
$16.24
-0.0100 (-0.0615%)
At Close: Jun 03, 2026
Sarepta Therapeutics to Announce Third Quarter 2021 Financial Results and Recent Corporate Developments on November 3, 2021
08:30am, Wednesday, 27'th Oct 2021
CAMBRIDGE, Mass., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2021 financial resul
Is This Beaten Down Biotech a Bad News Buy?
07:00am, Wednesday, 20'th Oct 2021
It has lagged the market over the last five years but with a promising gene therapy, is Sarepta worth another look?
What's Next For Sarepta Stock After A 12% Fall?
09:45am, Monday, 18'th Oct 2021
The stock price of Sarepta Therapeutics, a biotech company focused on the discovery and development of RNA-targeted therapeutics and gene therapy for the treatment of rare diseases, plunged 12% yester
4 Biotechs to Watch Amid Rising Prominence of Gene Therapies
12:38pm, Thursday, 14'th Oct 2021
Here we discuss four biotech companies, CRSP, EDIT, SRPT and BEAM, that have the potential to gain from their promising gene therapy pipeline candidates.
Sarepta Therapeutics Announces Pricing of $500 Million Public Offering of Common Stock
09:15pm, Wednesday, 13'th Oct 2021
CAMBRIDGE, Mass., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it has priced an underwri
Why Sarepta Therapeutics Tumbled Today
04:47pm, Wednesday, 13'th Oct 2021
Investors weren't wowed by a company update, or by news of a fresh stock issue.
Sarepta Therapeutics Announces Preliminary Financial Results for the Third Quar-ter Ended September 30, 2021
04:04pm, Tuesday, 12'th Oct 2021
CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced preliminary financial results
Sarepta Therapeutics Announces Proposed $500,000,000 Public Offering of Common Stock
04:01pm, Tuesday, 12'th Oct 2021
CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (Nasdaq:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it is offering to sell, s
Sarepta's Duchenne Gene Therapy Shows Sustained Functional Improvements
03:25pm, Monday, 11'th Oct 2021
Sarepta Therapeutics Inc (NASDAQ: SRPT) shared new analyses and functional data from its SRP-9001 development program and the details of Study SRP-9001-301 (EMBARK) Phase 3 trial of SRP-9001 for Du
Sarepta Therapeutics' SRP-9001 Shows Sustained Functional Improvements in Multiple Studies of Patients with Duchenne
09:13am, Monday, 11'th Oct 2021
CAMBRIDGE, Mass., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today shared new analyses and functional data
Sarepta, Codiak Nix Exosome Therapy Development Pact
01:02pm, Friday, 08'th Oct 2021
Sarepta Therapeutics Inc (NASDAQ: SRPT) notified Codiak BioSciences Inc (NASDAQ: CDAK) that it would terminate the two-year Research License and Option agreement early. The termination will be
Sarepta Therapeutics Opens Genetic Therapies Center of Excellence in Columbus, Ohio
04:30pm, Monday, 04'th Oct 2021
CAMBRIDGE, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today celebrated the grand opening of the Gene
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:06pm, Thursday, 30'th Sep 2021
CAMBRIDGE, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on September 30, 2021 t
Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram Presents at Cantor Fitzgerald 2021 Virtual Global Healthcare Conference (Transcript)
- Company Anticipates Part B of MOMENTUM to Serve as Pivotal Study for SRP-5051 and to Seek Accelerated Approval if Successful - Ambulatory and Non-Ambulatory Patients Between the Ages of 7 to 21
